Ocular surface parameters
acne
DISEASE, MEIBOMIAN GLAND DYSFUNCTION, ACNE
This study included 30 consecutive patients (60 eyes), six male (12 eyes) and 24 female (48 eyes) individuals, with a mean age of 66.0 ± 8.8 years (range 43–80). Four weeks after the last IPL treatment during which other conventional MGD treatments were restricted, the tear break-up time (TBUT) (from 2.09 ± 1.16 to 4.08 ± 1.52, p < 0.001), Sjögren's International Collaborative Clinical Alliance (SICCA) staining score (from 6.50 ± 2.16 to 3.00 ± 1.87, p < 0.001), Oxford staining score (from 2.65 ± 1.05 to 0.93 ± 0.73, p < 0.001), and Ocular Surface Disease Index (OSDI) score (from 61.69 ± 20.62 to 40.48 ± 19.07, p < 0.001) significantly improved when combining the results from both filters (Table Comparison of clinical signs and symptoms before treatment and 4 weeks after the last treatment of intense pulsed light (IPL) regardless of filter type (590-nm or acne filter) in patients with moderate to severe meibomian gland dysfunction.Results are presented as mean (standard deviation).IPL, intense pulsed light; TBUT, tear film break-up time; SICCA, Sjögren's International Clinical Collaborative Alliance; OSDI, ocular surface disease index; MMP-9, matrix metalloproteinase-9.Comparison of clinical signs and symptoms before treatment and 4 weeks after the last treatment of intense pulsed light (IPL) with each filter (590-nm or acne filter) in patients with moderate to severe meibomian gland dysfunction.Results are presented as mean (standard deviation).IPL, intense pulsed light; TBUT, tear film break-up time; SICCA, Sjögren's International Clinical Collaborative Alliance; MMP-9, matrix metalloproteinase-9.Comparison of clinical parameters after intense pulsed light (IPL) treatment between acne and 590-nm filters.Results are presented as mean (standard deviation).TBUT, tear film break-up time; SICCA, Sjögren's International Clinical Collaborative Alliance; MMP-9, matrix metalloproteinase-9.